PanCD44 Immunohistochemical Evaluation in Prostatectomies from Patients with Adenocarcinoma.
Carlos Gustavo HirthAdriele Machado Dos SantosJoão Batista Gadelha de CerqueiraFrancisco Vagnaldo Fechine JamacaruMaria do Perpétuo Socorro Saldanha da CunhaConceição Aparecida DornelasPublished in: BioMed research international (2018)
In the bulk of cells, the minority of cancer stem cells would not be detected by immunohistochemistry using panCD44. As a prognostic marker, its expression was weakly correlated with Gleason score and preoperative PSA level, but not with surgical margin status, tumor stage, or BR.